Cue biopharma reports second quarter 2025 financial results and recent business highlights

Boston, aug. 12, 2025 (globe newswire) -- cue biopharma, inc.  (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of autoimmune disease and cancer, today provided a business and financial update for the second quarter 2025.
CUE Ratings Summary
CUE Quant Ranking